US2020316158A1PendingUtilityA1

Collagen 7 compositions and methods of using the same

Assignee: PHOENIX TISSUE REPAIR INCPriority: Dec 23, 2015Filed: May 15, 2020Published: Oct 8, 2020
Est. expiryDec 23, 2035(~9.4 yrs left)· nominal 20-yr term from priority
A61K 38/39A61P 17/02A61K 47/26A61K 47/183C07K 14/78A61Q 19/08A61K 38/014A61K 8/65A61K 8/60A61K 8/4993A61K 8/44A61K 8/24A61K 8/20A61K 47/10A61K 9/0019
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to compositions comprising collagen 7 and methods of using the same to treat DEB.

Claims

exact text as granted — not AI-modified
1 . A composition comprising at least 0.5 mg/ml recombinant collagen 7 (rCo17) in a formulation comprising arginine. 
     
     
         2 . The composition of  claim 1 , wherein rCol7 is at a concentration of about 1.0 mg/ml to about 4.0 mg/ml. 
     
     
         3 . The composition of  claim 2 , wherein rCol7 is at a concentration of about 1.0 mg/ml to about 2.0 mg/ml. 
     
     
         4 . The composition of  claim 3 , wherein the formulation further comprises 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose and 0.05% (v/v) polysorbate 20. 
     
     
         5 . The composition of  claim 4  for use of medicine administered to a subject in need through infusion wherein the infusion lasts at least 60 minutes. 
     
     
         6 . A method for treating dystrophic epidermolysis bullosa comprising administering to a subject in need thereof an effective amount of a composition that comprises about 1.0 mg/ml to about 4.0 mg/ml recombinant collagen 7. 
     
     
         7 . The method of  claim 6  wherein the composition is administrated to the subject in need by intravenous administration. 
     
     
         8 . A method for increasing closure between epidermis and dermis of the wounded skin in a subject comprising administering to the subject a composition comprising a recombinant collagen 7 in an arginine containing formulation. 
     
     
         9 . The method of  claim 8  wherein the composition is administrated to the subject in need by intravenous administration. 
     
     
         10 . The method of  claim 6  wherein the composition comprises about 1.0 mg/ml to about 2.0 mg/ml recombinant collagen 7. 
     
     
         11 . The method of  claim 10  wherein the composition further comprises 10 mM sodium phosphate, 5 mM sodium citrate, 70 mM sodium chloride, 100 mM arginine, 50 mM sucrose and 0.05% (v/v) polysorbate 20.

Join the waitlist — get patent alerts

Track US2020316158A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.